TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...
In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...
CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory ...
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s ...
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable ...
Wellbeing Magazine on MSN
Travel vaccinations for Southeast Asia from the UK: Vaccines, health risks & pre-travel checklist
Southeast Asia is a popular long-haul destination for UK travellers, attracting millions to countries like Thailand, Vietnam, Cambodia, Indonesia, the Philippines, and Malaysia. The post Travel ...
Plainview Herald on MSN
This And That: Hale Center Lions Club brings circus to Hale Center
The Culpepper & Merriweather Circus is set to stop in Hale Center at Borden Park on April 6.
News-Medical.Net on MSN
This doctor-senator who backed RFK Jr. now faces a fight for his job — and his legacy
The ambitious liver doctor would go just about anywhere in his home state to give people the hepatitis B vaccine. Bill Cassidy offered jabs to thousands of inmates at Louisiana's maximum-security ...
Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical ...
Sudan News Agency (SUNA) on MSN
Scientific forum in preparation for the launch of the birth dose of the hepatitis B vaccine
Khartoum, March 5, 2026 (SUNA) – In preparation for the launch of the birth dose of the Hepatitis B vaccine into the routine immunization schedule, the Federal Ministry of Health on Thursday organized ...
The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appealIf the $1.3 billion payment is realized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results